All other authors declare no conflicts of interest
10.1007/s00125-011-2241-2
Our methodology included: Reviewed IVY RX public website disclosures and published program information Reviewed FDA guidance on compounded GLP-1 medications, including enforcement discretion policies and safety communications Evaluated program structure, pricing transparency, and safety disclosures as presented on the company's website Did not evaluate effectiveness, outcomes, or patient results Did not perform medical testing or make clinical recommendations This article is educational and presents information for readers to consider when making their own healthcare decisions in consultation with licensed providers
Moyer A, Salavaggione O, Hebbring S, Moon I, Hildebrandt MA , Eckloff B, Schaid D, Wieben E, Weinshilboum R
Our licensed providers take time to listen to your story, answer your questions, and help determine if a medication like semaglutide or tirzepatide is the right fit for your health goals
